| Q39248316 | 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma |
| Q37086063 | A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. |
| Q39575536 | Attenuated mumps virus therapy of carcinoma of the maxillary sinus |
| Q39477334 | Chapter 10 Viral infections of lower motor neurons. |
| Q45868174 | Conditionally replicative adenoviruses for cancer therapy |
| Q42654000 | Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma |
| Q26797520 | Going viral: a review of replication-selective oncolytic adenoviruses |
| Q34575505 | History of oncolytic viruses: genesis to genetic engineering |
| Q34436502 | Management of high-risk melanoma |
| Q37388577 | Measles virus for cancer therapy |
| Q33841589 | Newcastle disease virus (NDV): brief history of its oncolytic strains |
| Q45371048 | Oncolytic vaccinia virus: a silver bullet? |
| Q38881477 | Oncolytic virus as a cancer stem cell killer: progress and challenges |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q45717443 | Present status of oncolytic virus studies |
| Q57183554 | Progress in gene therapy using oncolytic vaccinia virus as vectors |
| Q37191007 | Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded |
| Q78638227 | The influence of viruses on the evolution of some malignant tumors |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
| Q51846287 | Tumor Restrictions to Oncolytic Virus. |